- Regional Meeting, Cambridge 18 May 2018
Regional Meeting, Cambridge 18 May 2018
The 2018 Regional Meeting will be held at the Li Ka Shing Centre, Addenbrooke’s Hospital on Friday 18 May. The organisers are Dr Pippa Corrie and Dr Christine Parkinson of Cambridge University Hospitals NHS Foundation Trust.
CPD accreditation has been granted by the RCP, the RCS and BAPRAS.
We welcome posters at this meeting. Abstracts should be submitted to email@example.com, as soon as possible. Posters will be assessed during the day of the meeting and a prize awarded to the winner.
Earlybird discounts are available for a few more days, so don’t delay if you want to attend: follow this link for information on meeting fees and how to register.
For travel directions see this Summary and the Getting to CRUK CI guide.
Welcome and Introduction
Professor Marc Moncrieff, Norfolk and Norwich University NHS Foundation Trust:
Update on national melanoma database
Session 1: Genetic predisposition, patterns of relapse and early detection of melanoma
Dr Erik Larsson Lekholm, Cancer Research UK Cambridge Institute:
Melanoma risk assessment and UV exposure
Dr Roy Rabbie, Wellcome Sanger Institute:
Prognostic factors and predictors of patterns of recurrence
Jonathan Wan, Cancer Research UK Cambridge Institute:
Detection of residual disease using ctDNA
Session 2: Immune checkpoint toxicity
Patient experience – immune checkpoint GI toxicity
Dr Tim Raine, Cambridge University Hospitals NHS Foundation Trust:
Case presentation of immune checkpoint GI toxicity
Dr Trevor Lawley, Wellcome Sanger Institute:
Immune checkpoint GI toxicity and the microbiome
Discussion of management of GI checkpoint inhibitor toxicities
Controversies in metastatic melanoma systemic therapy 1:
Should pre-existing auto-immunity or treatment-induced irAEs influence subsequent use of checkpoint inhibitors?
Lunch and Poster Judging
Session 3: Melanoma trials
Professor Jeffrey Weber, NYU Langone Medical Center, Perlmutter Cancer Center:
Adjuvant treatment of melanoma
Controversies in metastatic melanoma systemic therapy 2:
How should we schedule targeted therapy and checkpoint inhibitors?
Professor Poulam Patel, Chair, NCRI Skin CSG:
Update on the NIHR melanoma trials portfolio
Session 4: Surgical management of resectable disease
Mr Howard Peach, Leeds Teaching Hospitals NHS Trust:
Summary and Close